JP2007530595A5 - - Google Patents

Download PDF

Info

Publication number
JP2007530595A5
JP2007530595A5 JP2007505245A JP2007505245A JP2007530595A5 JP 2007530595 A5 JP2007530595 A5 JP 2007530595A5 JP 2007505245 A JP2007505245 A JP 2007505245A JP 2007505245 A JP2007505245 A JP 2007505245A JP 2007530595 A5 JP2007530595 A5 JP 2007530595A5
Authority
JP
Japan
Prior art keywords
compound
agent
heteroatoms
independently
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007505245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530595A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from US11/089,701 external-priority patent/US7462612B2/en
Publication of JP2007530595A publication Critical patent/JP2007530595A/ja
Publication of JP2007530595A5 publication Critical patent/JP2007530595A5/ja
Pending legal-status Critical Current

Links

JP2007505245A 2004-03-26 2005-03-25 Erk2のピリジンインヒビターおよびそれらの使用 Pending JP2007530595A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55676604P 2004-03-26 2004-03-26
US11/089,701 US7462612B2 (en) 2004-03-26 2005-03-25 Pyridine inhibitors of ERK2 and uses thereof
PCT/US2005/010204 WO2005100342A1 (en) 2004-03-26 2005-03-25 Pyridine inhibitors of erk2 and uses thereof

Publications (2)

Publication Number Publication Date
JP2007530595A JP2007530595A (ja) 2007-11-01
JP2007530595A5 true JP2007530595A5 (cg-RX-API-DMAC10.html) 2008-05-08

Family

ID=34964893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505245A Pending JP2007530595A (ja) 2004-03-26 2005-03-25 Erk2のピリジンインヒビターおよびそれらの使用

Country Status (4)

Country Link
US (1) US7462612B2 (cg-RX-API-DMAC10.html)
EP (1) EP1730134A1 (cg-RX-API-DMAC10.html)
JP (1) JP2007530595A (cg-RX-API-DMAC10.html)
WO (1) WO2005100342A1 (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087548A2 (en) * 2005-02-18 2006-08-24 Astrazeneca Ab Pyrrole derivatives as dna gyrase and topoisomerase inhibitors
EP1879881A2 (en) * 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CN101253152A (zh) 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Erkインヒビターとしてのピロリジン誘導体
EP2032562B1 (en) * 2006-05-12 2010-08-25 Vertex Pharmaceuticals Incorporated Selective inhibitors of rock protein kinase and uses thereof
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
CA2663436A1 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
CN101611007A (zh) * 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CA2696349A1 (en) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
CN102015693B (zh) 2008-02-21 2014-10-29 默沙东公司 作为erk抑制剂的化合物
CN102388054B (zh) 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物
JP5502397B2 (ja) * 2009-08-25 2014-05-28 公益財団法人微生物化学研究会 新規化合物アミコロース誘導体、並びにその製造方法及びその用途
CN103420902A (zh) * 2012-05-18 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种2-氯-4-碘-5-甲基吡啶的制备方法
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
CN103193704B (zh) * 2013-04-12 2016-03-09 四川铂瑞生物医药有限公司 2-羟基-4-氨基-5-甲基吡啶杂环化合物
US20160264536A1 (en) * 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US20190073895A1 (en) * 2017-09-07 2019-03-07 Timetec Holding Sdn Bhd Alarm system
AU2020230965A1 (en) 2019-03-05 2021-09-23 Bayer Aktiengesellschaft Synthesis of 4-amino-5-methyl-1H-pyridin-2(1H)-on (intermediate compound for the synthesis of the MR antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine
CN113929591A (zh) * 2021-10-09 2022-01-14 中国科学技术大学 具有抗增殖活性的抑制剂
CN117024335A (zh) * 2023-07-10 2023-11-10 杭州小蓓医药科技有限公司 一种非奈利酮中间体4-氨基-5-甲基-1h-吡啶-2(i)-酮的合成工艺
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1274295A (en) 1993-12-30 1995-07-17 Ciba-Geigy Ag Heteroarylpyrroles
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
JP4783532B2 (ja) * 2000-02-05 2011-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド Erkのインヒビターとして有用なピラゾール組成物
EP1506189A1 (en) * 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
BR0317430A (pt) * 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
CA2515132C (en) 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
ES2897422T3 (es) * 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos

Similar Documents

Publication Publication Date Title
EP1865958B1 (en) Pharmacokinetically improved compounds
CN1113066C (zh) 新型肽衍生物
JP2007501257A5 (cg-RX-API-DMAC10.html)
JP2010532380A5 (cg-RX-API-DMAC10.html)
JP2006520386A5 (cg-RX-API-DMAC10.html)
JP2020528907A5 (cg-RX-API-DMAC10.html)
CA2755095A1 (en) Rho kinase inhibitors
CN1161330A (zh) 取代的间二氮杂萘衍生物
JP2006522124A5 (cg-RX-API-DMAC10.html)
JP2020055828A5 (cg-RX-API-DMAC10.html)
KR20100099116A (ko) 리버스턴 유사체의 신규 화합물 및 그의 용도(2)
JP2008528671A5 (cg-RX-API-DMAC10.html)
EP3277276A1 (en) Methods of administering glutaminase inhibitors
JP2017214420A5 (cg-RX-API-DMAC10.html)
JP2014055136A (ja) 薬物動態が改善された化合物
JP6785801B2 (ja) 新しいキャップ基ラルガゾールの類似体の合成及び使用
RU2006144448A (ru) Пролекарства пирролилпиримидиновых ингибиторов протеинкиназы erk
KR20230118854A (ko) IRE1α 억제제 및 이의 용도
US12357612B2 (en) Prophylactic or therapeutic agent for cancer
US20130345281A1 (en) Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
TWI234457B (en) Camptothecin-taxoid conjugates as antimitotic and antitumor agents
CN101193861A (zh) 具有抗肿瘤活性的吲哚衍生物
CN109152750A (zh) 用于增殖性疾病的组合疗法
ES2222988T3 (es) Formas de sal especificas de derivados de trifeniletileno como moduladores selectivos de los receptores de estrogenos.
JP2007507473A5 (cg-RX-API-DMAC10.html)